Abstract
Metabolic Syndrome (MetS) is a complex disorder defined by the aggregation of interconnected cardiometabolic risk factors which increase the risk of diabetes mellitus type 2 and cardiovascular disease (CVD). MetS is currently a matter of concern and it will continue to be in the future, since there is likely to be a dramatic increase in its prevalence, and subjects with MetS will have an increased risk of mortality, mainly through CVD. Moreover, the implications on the global health burden and the worldwide epidemic of this complex disorder will impact greatly on socioeconomic cost. MetS is therefore a matter of serious concern and we need to understand its etiology in order to improve strategies of treatment and prevention. In this regard, postprandial lipemia has increased in importance over the last few years as it has been demonstrated to influence the development of atherosclerosis. In addition, in modern times, fasting is not the typical physiological state of humans; in fact, they spend most of the time in the postprandial state. However, although it is obvious that postprandial lipemia is present in conditions of obesity, little is known about the relevance of postprandial lipemia in MetS. In the current review, we will explore some aspects of postprandial lipemia which could be of interest for understanding the pathogenesis of this complex disorder and which may help us advance towards more personalized nutrition.
Keywords: Endothelial dysfunction, inflammation, metabolic syndrome, nutrigenetics, oxidative stress, postprandial lipemia.
Current Vascular Pharmacology
Title:Relevance of Postprandial Lipemia in Metabolic Syndrome
Volume: 11 Issue: 6
Author(s): Antonio Garcia-Rios, Javier Delgado-Lista, Pablo Perez-Martinez, Nieves Delgado-Casado, Francisco Perez-Jimenez and Jose Lopez-Miranda
Affiliation:
Keywords: Endothelial dysfunction, inflammation, metabolic syndrome, nutrigenetics, oxidative stress, postprandial lipemia.
Abstract: Metabolic Syndrome (MetS) is a complex disorder defined by the aggregation of interconnected cardiometabolic risk factors which increase the risk of diabetes mellitus type 2 and cardiovascular disease (CVD). MetS is currently a matter of concern and it will continue to be in the future, since there is likely to be a dramatic increase in its prevalence, and subjects with MetS will have an increased risk of mortality, mainly through CVD. Moreover, the implications on the global health burden and the worldwide epidemic of this complex disorder will impact greatly on socioeconomic cost. MetS is therefore a matter of serious concern and we need to understand its etiology in order to improve strategies of treatment and prevention. In this regard, postprandial lipemia has increased in importance over the last few years as it has been demonstrated to influence the development of atherosclerosis. In addition, in modern times, fasting is not the typical physiological state of humans; in fact, they spend most of the time in the postprandial state. However, although it is obvious that postprandial lipemia is present in conditions of obesity, little is known about the relevance of postprandial lipemia in MetS. In the current review, we will explore some aspects of postprandial lipemia which could be of interest for understanding the pathogenesis of this complex disorder and which may help us advance towards more personalized nutrition.
Export Options
About this article
Cite this article as:
Garcia-Rios Antonio, Delgado-Lista Javier, Perez-Martinez Pablo, Delgado-Casado Nieves, Perez-Jimenez Francisco and Lopez-Miranda Jose, Relevance of Postprandial Lipemia in Metabolic Syndrome, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/15701611113116660172
DOI https://dx.doi.org/10.2174/15701611113116660172 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Renal Artery Stenting: Efficacy and Complications
Current Hypertension Reviews Cardiovascular Complications in Patients with Turner’s Syndrome
Current Pharmaceutical Design Diagnostic Value of Assessment of Serum Cortisol, Hepcidin and Thyroid Hormones Levels in Neonates with Late-Onset Sepsis
Infectious Disorders - Drug Targets Characterization of Optimized Functional-Complementary Dual Insulinotorpic Peptide rolGG
Current Pharmaceutical Biotechnology Clinical Importance of Calcium-Sensing Receptor Gene Polymorphism Arg990Gly in the Age of Calcimimetic Therapy
Current Pharmacogenomics α-Glucosidase Inhibitory Effect and Antioxidant Activity of the Extracts of Eighteen Plant Traditionally Used in Algeria for Diabetes
Current Enzyme Inhibition Soluble (Pro) Renin Receptor is a Predictor of Gestational Diabetes Mellitus
Current Diabetes Reviews The Role of Tirofiban in the Management of Coronary Artery Disease
Cardiovascular & Hematological Disorders-Drug Targets Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology Identification of Site(s) of Insulin Nitration by Peroxynitrite and Characterization of Its Structural Change
Protein & Peptide Letters The Impact of Asymmetric Dimethylarginine (ADAMA), the Endogenous Nitric Oxide (NO) Synthase Inhibitor, to the Pathogenesis of Gastric Mucosal Damage
Current Pharmaceutical Design Regulation of the DNA Damage Response to DSBs by Post-Translational Modifications
Current Genomics Emerging Targets for the Treatment of Dyslipidemia
Current Medicinal Chemistry Cerium and Yttrium Oxide Nanoparticles and Nano-selenium Produce Protective Effects Against H2O2-induced Oxidative Stress in Pancreatic Beta Cells by Modulating Mitochondrial Dysfunction
Pharmaceutical Nanotechnology Mango Polyphenols and Its Protective Effects on Diseases Associated to Oxidative Stress
Current Pharmaceutical Biotechnology The Potential Role of Thiamine (Vitamin B1) in Diabetic Complications
Current Diabetes Reviews Clozapine Safety, 40 Years Later
Current Drug Safety Association of Red Blood Cell Indices with Mild Cognitive Impairment in Chinese Elderly Individuals: A Matched Case-control Study
Current Alzheimer Research Mesenchymal Stem Cell Therapy in Intracerebral Haemorrhagic Stroke
Current Medicinal Chemistry Nutrigenomics, β-Cell Function and Type 2 Diabetes
Current Genomics